Joint analysis of two phase 2 RCTs (79 participants, EGFR-mutant NSCLC with brain metastases): adding upfront stereotactic radiosurgery to osimertinib did not significantly improve 12-month intracranial PFS (difference 11%, p=0.31). Grade 3/4 radionecrosis in 5% with SRS.
RCTn = 79
Lee et al. Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials